Use of Yescarta in Acute Lymphoblastic Leukemia Yescarta (axicabtagene ciloleucel) is also under late Phase 1 research for treatment of refractory or relapsed acute lymphoblastic leukemia (r/r ALL). ALL is …
CAR T-Cell Therapy HCP Guide – Use of Yescarta in Acute Lymphoblastic Leukemia Read More
October 17, 2017 (Medical News Today) Scientists and researchers from the UK have set out to investigate why cancer often returns in patients whose cancers have become dormant, focusing especially …
Cancer recurrence may be stopped with immunotherapy Read More
Creating a universal CAR T agent could help avoid the lengthy and sometimes dangerous time period from apheresis of T-cells to re-infusion, which on average runs 2 to 2.5 weeks, …
CAR T-Cell Therapy HCP Guide – Is There A Universal CAR-T Cell Therapy? Read More
While side effects can be challenging, the fact remains that complete and partial remissions are impressive with CAR T-cell therapy. All eligible patients have exhausted their cancer treatment options, and …
CAR T-Cell Therapy HCP Guide – What Studies Are Ongoing With CAR T-Cell Therapy? Read More
At a July 2017 FDA Oncology Advisory Committee meeting, the panel reviewed Novartis’ CTL019 (tisagenlecleucel), an agent for aggressive pediatric and young adult acute B-cell acute lymphoblastic leukemia (ALL). The …
CAR T-Cell Therapy HCP Guide – Is CAR T-Cell Therapy Approved? Read More